Navigation Links
Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
Date:3/18/2008

- Data demonstrates mortality reduction in endotoxemic patients through use

of combined diagnostic and therapeutic -

TORONTO, March 18 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced that new findings were presented showing a mortality reduction in endotoxemic patients through the combined use of Spectral's EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin, and Toray Medical Company's Toraymyxin(TM) column, a blood purification device that absorbs endotoxin from the bloodstream. The findings will be presented in a symposium entitled "Measuring and targeting endotoxin in critical illness - from theory to practice" at the 28th International Symposium on Intensive Care and Emergency Medicine. The conference takes place in Brussels, Belgium from March 18-21, 2008 and focuses on developments in research, therapy, and management of critically ill patients.

"Our unique EAA(TM) diagnostic offers critical care physicians valuable information on the diagnosis of endotoxemia. Used in combination with Toray's therapy, EAA(TM) provides actionable data that has the potential to lead to a reduction in mortality as demonstrated by the findings presented at this important conference," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Toraymyxin(TM) is highly effective in removing endotoxin from the bloodstream and our EAA(TM) product has the ability to identify patients who could benefit from the therapy and monitor its results. Together, the combined diagnostic and therapeutic has the potential to provide a more effective treatment for patients with endotoxemia."

Data compiled using Spectral's EAA(TM) will also be featured in several posters being presented at the conference. A manuscript describing the study of the combined use of EAA(TM) and Toraymyxin(TM) is currently being written and will be submitted for publication in 2008.

About Spectral Diagnostics

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral announces 2007 financial results
2. Spectral appoints Anthony Bihl to Board of Directors
3. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
4. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
5. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
6. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
7. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
8. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
9. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
10. Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results
11. USP Announces Revised Glycerin Monograph
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):